[go: up one dir, main page]

ES2678696T3 - Proteínas de fusión dirigidas/inmunomoduladoras y métodos de preparación de las mismas - Google Patents

Proteínas de fusión dirigidas/inmunomoduladoras y métodos de preparación de las mismas Download PDF

Info

Publication number
ES2678696T3
ES2678696T3 ES13734158T ES13734158T ES2678696T3 ES 2678696 T3 ES2678696 T3 ES 2678696T3 ES 13734158 T ES13734158 T ES 13734158T ES 13734158 T ES13734158 T ES 13734158T ES 2678696 T3 ES2678696 T3 ES 2678696T3
Authority
ES
Spain
Prior art keywords
seq
amino acid
spacer
moiety
targeted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13734158T
Other languages
English (en)
Inventor
Nagaraj Govindappa
Kedarnath Sastry
Maria Melina SOARES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocon Ltd
Original Assignee
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54196717&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2678696(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocon Ltd filed Critical Biocon Ltd
Application granted granted Critical
Publication of ES2678696T3 publication Critical patent/ES2678696T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/22—Zinc; Zn chelators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)

Abstract

Una proteína de fusión quimérica que consiste en un resto de direccionamiento para dirigir a una célula cancerosa, un resto inmunomodulador que contrarresta la tolerancia inmunitaria, y un espaciador de aminoácidos, en la que el resto de direccionamiento y el resto inmunomodulador están unidos por un espaciador de aminoácidos de longitud suficiente de restos de aminoácidos de manera que ambos restos puedan unirse satisfactoriamente a su diana individual, en la que el resto inmunomodulador es TGF-ßRII que consiste en la secuencia de aminoácidos de SEQ ID NO: 4; en la que el espaciador de aminoácidos es SEQ ID NO: 3 o SEQ ID NO:11; y en la que el resto de direccionamiento es anti-EGFR1 que consiste en la cadena pesada SEQ ID NO: 5 y la cadena ligera SEQ ID NO: 6; en la que SEQ ID NO: 4 está unida mediante el espaciador de aminoácidos al extremo C de SEQ ID NO: 5 o SEQ ID NO: 6 de anti-EGFR1.
ES13734158T 2012-04-30 2013-03-13 Proteínas de fusión dirigidas/inmunomoduladoras y métodos de preparación de las mismas Active ES2678696T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1689CH2012 2012-04-30
IN1690CH2012 2012-04-30
PCT/IB2013/001155 WO2013164694A1 (en) 2012-04-30 2013-03-13 Targeted/immunomodulatory fusion proteins and methods for making same

Publications (1)

Publication Number Publication Date
ES2678696T3 true ES2678696T3 (es) 2018-08-16

Family

ID=54196717

Family Applications (2)

Application Number Title Priority Date Filing Date
ES18212095T Active ES2938182T3 (es) 2012-04-30 2013-03-13 Proteínas de fusión dirigidas/inmunomoduladoras y métodos de preparación de las mismas
ES13734158T Active ES2678696T3 (es) 2012-04-30 2013-03-13 Proteínas de fusión dirigidas/inmunomoduladoras y métodos de preparación de las mismas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES18212095T Active ES2938182T3 (es) 2012-04-30 2013-03-13 Proteínas de fusión dirigidas/inmunomoduladoras y métodos de preparación de las mismas

Country Status (15)

Country Link
US (10) US8815247B2 (es)
EP (4) EP4219536A3 (es)
JP (4) JP6357467B2 (es)
CN (4) CN110041431A (es)
AU (2) AU2013255542C1 (es)
CA (4) CA2947354C (es)
DK (2) DK3489254T3 (es)
ES (2) ES2938182T3 (es)
HK (2) HK1202295A1 (es)
MY (1) MY174248A (es)
NZ (4) NZ714549A (es)
PL (2) PL3489254T3 (es)
PT (2) PT2844667T (es)
RU (1) RU2636342C2 (es)
WO (1) WO2013164694A1 (es)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL300733B1 (en) 2010-03-05 2025-10-01 Univ Johns Hopkins Compositions and methods for antibodies and fusion proteins targeted for immune modulation
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
EP4219536A3 (en) * 2012-04-30 2023-08-23 Biocon Limited Targeted/immunomodulatory fusion proteins and methods for making same
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
HRP20191865T1 (hr) 2013-01-14 2020-01-10 Xencor, Inc. Novi heterodimerni proteini
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
PT2970512T (pt) * 2013-03-12 2019-01-17 Biocon Ltd Proteínas de fusão imunomoduladoras e métodos para produção das mesmas
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
CN105658672A (zh) 2013-08-22 2016-06-08 阿塞勒隆制药公司 TGF-β受体II型变体及其用途
US20160367651A1 (en) * 2013-10-01 2016-12-22 Mie University T cell inducing vaccine containing an interepitope sequence that promotes antigen presentation
EP2891664A1 (en) * 2014-01-07 2015-07-08 Technische Universität München Novel methods for the stabilisation of immunoglobulin constant domains
AU2015205530B8 (en) * 2014-01-13 2019-09-19 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
SG11201606577YA (en) * 2014-02-10 2016-09-29 Merck Patent Gmbh TARGETED TGFβ INHIBITION
EP3954713A3 (en) 2014-03-28 2022-03-30 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
US10351621B2 (en) 2014-06-24 2019-07-16 Immunomedics, Inc. Anti-histone therapy in acute kidney injury
WO2015200260A1 (en) * 2014-06-24 2015-12-30 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
CA2963718A1 (en) 2014-11-14 2016-05-19 F. Hoffmann-La Roche Ag Antigen binding molecules comprising a tnf family ligand trimer
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EP3223907A2 (en) 2014-11-26 2017-10-04 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
CN116333153A (zh) 2014-11-26 2023-06-27 森科股份有限公司 结合cd3和肿瘤抗原的异二聚体抗体
WO2016156291A1 (en) 2015-03-31 2016-10-06 F. Hoffmann-La Roche Ag Antigen binding molecules comprising a trimeric tnf family ligand
CN107636014B (zh) * 2015-05-04 2021-12-07 皮里斯制药有限公司 抗癌融合多肽
WO2017019729A1 (en) 2015-07-27 2017-02-02 The General Hospital Corporation Antibody derivatives with conditionally enabled effector function
CN116327952A (zh) 2015-08-04 2023-06-27 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
EP3344660B1 (en) 2015-08-31 2025-03-05 National Research Council of Canada Tgf-beta-receptor ectodomain fusion molecules and uses thereof
JP2018531625A (ja) * 2015-09-11 2018-11-01 ナセント バイオテック インコーポレイテッド 脳への向上した薬物送達の方法
CN116063566A (zh) 2015-10-01 2023-05-05 热生物制品有限公司 作为异源嵌合蛋白邻接i型和ii型胞外结构域的组合物和方法
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
PE20180773A1 (es) 2015-10-02 2018-05-07 Hoffmann La Roche Anticuerpos biespecificos para pd1 y tim3
KR20180053674A (ko) 2015-10-02 2018-05-23 에프. 호프만-라 로슈 아게 공자극 tnf 수용체에 특이적인 이중특이성 항체
CR20180171A (es) * 2015-10-07 2018-05-03 Hoffmann La Roche Anticuerpos biespecíficos con tetravalencia para un receptor de fnt coestimulador
KR20180085800A (ko) 2015-12-07 2018-07-27 젠코어 인코포레이티드 Cd3 및 psma에 결합하는 이종이합체성 항체
EP3411414A4 (en) * 2016-02-05 2019-10-23 Washington University COMPOSITIONS AND METHOD FOR TARGETED CYTOKINE RELIEF
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
WO2017192536A1 (en) * 2016-05-02 2017-11-09 University Of Kansas Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
AR108377A1 (es) * 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
EP3243836A1 (en) * 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
EP3243832A1 (en) * 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
IL263542B2 (en) 2016-06-14 2024-10-01 Xencor Inc Bispecific antibodies inhibit immunological checkpoint
KR20190020341A (ko) 2016-06-28 2019-02-28 젠코어 인코포레이티드 소마토스타틴 수용체 2에 결합하는 이종이량체 항체
AU2017310027A1 (en) * 2016-08-12 2019-01-31 Merck Patent Gmbh Combination therapy for cancer
WO2018045110A1 (en) * 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
EP3519442A4 (en) 2016-09-27 2020-06-17 EpicentRx, Inc. Immunomodulatory fusion proteins
CA3037261A1 (en) * 2016-09-29 2018-04-05 Aebi Ltd. Therapeutic multi-targeting constructs and uses thereof
CN107915777A (zh) * 2016-10-09 2018-04-17 泰州迈博太科药业有限公司 一种重组免疫细胞因子及其应用
CN108250302A (zh) * 2016-12-29 2018-07-06 天津天锐生物科技有限公司 一种多功能蛋白质
HRP20220230T1 (hr) 2017-01-05 2022-04-29 Kahr Medical Ltd. Sirp1 alfa-41bbl fuzijski protein i metoda njegove upotrebe
IL267861B2 (en) * 2017-01-05 2025-02-01 Kahr Medical Ltd PD1-41BBL conjugated protein and methods of using the same
WO2018127916A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A pd1-cd70 fusion protein and methods of use thereof
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
CA3048646A1 (en) * 2017-01-07 2018-07-12 Merck Patent Gmbh Dosing regimens and dosage forms for targeted tgf-b inhibition
CN108440668A (zh) * 2017-02-16 2018-08-24 瑞阳(苏州)生物科技有限公司 Fgf21与igf-1的融合蛋白及其应用
US11192933B2 (en) 2017-02-27 2021-12-07 Shattuck Labs, Inc. VSIG8-based chimeric proteins
CN110234345A (zh) 2017-02-27 2019-09-13 沙塔克实验室有限公司 制备和使用基于细胞外结构域的嵌合蛋白的方法
CN110381974A (zh) 2017-02-27 2019-10-25 沙塔克实验室有限公司 基于csf1r的嵌合蛋白
EP3589663A4 (en) 2017-03-02 2020-10-21 National Research Council of Canada TGF-ß RECEPTOR ECTODOMAIN FUSION MOLECULES AND THEIR USES
CN116836285A (zh) 2017-03-09 2023-10-03 健玛保 针对pd-l1的抗体
CN107082812B (zh) 2017-03-29 2018-11-13 上海科医联创生物科技有限公司 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
PT3606946T (pt) 2017-04-03 2022-10-17 Hoffmann La Roche Imunoconjugados de um anticorpo anti-pd-1 com uma il-2 mutante ou com il-15
CN116375876A (zh) 2017-04-05 2023-07-04 豪夫迈·罗氏有限公司 特异性结合pd1和lag3的双特异性抗体
DK3628049T3 (da) 2017-05-04 2023-08-14 Acceleron Pharma Inc Tgf-beta-receptortype-ii-fusionsproteiner og anvendelser deraf
US11274142B2 (en) 2017-05-12 2022-03-15 Jiangsu Hengrui Medicine Co., Ltd. Fusion protein containing TGF-β receptor and medicinal uses thereof
US20200140547A1 (en) * 2017-05-26 2020-05-07 The Johns Hopkins University Multifunctional antibody-ligand traps to modulate immune tolerance
CA3071376A1 (en) 2017-08-03 2019-02-07 Amgen Inc. Interleukin-21 muteins and methods of treatment
JP7290013B2 (ja) 2017-08-04 2023-06-13 ジェンマブ エー／エス Ｐｄ－ｌ１およびｃｄ１３７に結合する結合物質ならびにその使用
IL273626B2 (en) 2017-09-27 2025-07-01 Epicentrx Inc Immunomodulatory fusion proteins
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
MX2020006322A (es) 2017-12-19 2020-09-18 Xencor Inc Proteinas de fusion il-2 fc modificadas.
MX2020007024A (es) 2018-01-03 2020-10-28 Palleon Pharmaceuticals Inc Sialidasas humanas recombinantes, proteinas de fusion de sialidasa y metodos para usar las mismas.
AU2019207895A1 (en) 2018-01-12 2020-06-18 Amgen Inc. Anti-PD-1 antibodies and methods of treatment
CN108285493B (zh) * 2018-02-02 2020-09-15 上海科医联创生物科技有限公司 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
CN112203681B (zh) * 2018-02-07 2024-05-24 免疫基因有限公司 疫苗组合物及其用途
TWI823906B (zh) 2018-03-09 2023-12-01 美商艾吉納斯公司 抗-cd73 抗體及其使用方法
TW202003011A (zh) * 2018-03-26 2020-01-16 美商艾爾特生物科技責任有限公司 抗ＰＤＬ１、ＩＬ－１５及ＴＧＦ－β受體組合分子
CN112469477A (zh) 2018-04-04 2021-03-09 Xencor股份有限公司 与成纤维细胞活化蛋白结合的异源二聚体抗体
WO2019197600A1 (en) * 2018-04-13 2019-10-17 F. Hoffmann-La Roche Ag Her2-targeting antigen binding molecules comprising 4-1bbl
EP3781598A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
AU2019256539A1 (en) 2018-04-18 2020-11-26 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
KR20210025525A (ko) 2018-06-22 2021-03-09 카이트 파마 인코포레이티드 키메라 막횡단 단백질 및 그의 용도
US11535669B2 (en) 2018-07-09 2022-12-27 Precigen, Inc. Fusion constructs and methods of using thereof
SG11202013167UA (en) 2018-07-11 2021-01-28 Kahr Medical Ltd SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
SG11202013170RA (en) 2018-07-11 2021-01-28 Kahr Medical Ltd Pd1-4-1bbl variant fusion protein and methods of use thereof
US10780121B2 (en) 2018-08-29 2020-09-22 Shattuck Labs, Inc. FLT3L-based chimeric proteins
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
CN120983617A (zh) 2018-11-06 2025-11-21 健玛保 抗体配制剂
MX2021005018A (es) 2018-11-09 2021-06-15 Jiangsu Hengrui Medicine Co Composicion farmaceutica de proteina de fusion del receptor tgf-?, y uso de la misma.
AU2020232605A1 (en) 2019-03-01 2021-10-21 Xencor, Inc. Heterodimeric antibodies that bind ENPP3 and CD3
CN110117329B (zh) * 2019-04-03 2020-12-08 河北浓孚雨生物科技有限公司 包含趋化因子与结合伴侣的融合多肽及其用途
US12325748B2 (en) * 2019-06-10 2025-06-10 Shandong Boan Biotechnology Co., Ltd. Bifunctional fusion protein against PDL1 and TGFβ and use thereof
BR112021025735A2 (pt) * 2019-06-21 2022-03-08 Kite Pharma Inc Receptores de tgf-ss e métodos de uso
WO2020263312A1 (en) * 2019-06-28 2020-12-30 Gensun Biopharma, Inc. ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFβ1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
WO2021003465A1 (en) * 2019-07-03 2021-01-07 Palleon Pharmaceuticals Inc. Sialidase-her2-antibody fusion proteins and methods of use thereof
EP3996730A2 (en) * 2019-07-09 2022-05-18 The Johns Hopkins University Molecules, compositions and methods for treatment of cancer
US20220267442A1 (en) * 2019-07-18 2022-08-25 Memorial Sloan Kettering Cancer Center METHODS AND COMPOSITIONS FOR TARGETING TGF-ß SIGNALING IN CD4+ HELPER T CELLS FOR CANCER IMMUNOTHERAPY
CN110540601B (zh) * 2019-07-29 2021-06-29 因之彩生物科技（武汉）有限公司 重组PLB-hEGF融合蛋白及其应用
CN110354260B (zh) * 2019-08-19 2020-06-26 启辰生生物科技(珠海)有限公司 免疫增强剂、药物组合物及其应用
CA3151030A1 (en) * 2019-09-12 2021-04-01 David M. Evans Co-delivery of tgf-.beta. sirna and pdl1 sirna to treat cancer
US20220411513A1 (en) * 2019-09-30 2022-12-29 Harbour Biomed (Shanghai) Co., Ltd Anti-pd-l1 antigen binding protein and application thereof
JP7495489B2 (ja) * 2019-10-21 2024-06-04 ナンチン リーズ バイオラブス カンパニー，リミティド ＰＤ－１およびＴＧＦβを標的化する組換えタンパク質
CN111018989B (zh) * 2019-12-16 2021-03-23 郑州大学 一种抗pd-l1单克隆抗体以及在制备抗癌药物方面的应用
CN111690070A (zh) * 2020-05-13 2020-09-22 深圳市众循精准医学研究院 一种sPD-1-Fc-sTGFβRII融合蛋白及其应用
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
WO2022011256A1 (en) 2020-07-10 2022-01-13 Precigen, Inc. Fusion constructs and methods of using thereof
US11028174B1 (en) 2020-07-28 2021-06-08 Lepu Biopharma Co., Ltd. Bifunctional molecules targeting PD-L1 and TGF-β
KR102607909B1 (ko) 2020-08-19 2023-12-01 젠코어 인코포레이티드 항-cd28 조성물
CN114539415B (zh) * 2020-11-24 2024-02-02 普米斯生物技术(珠海)有限公司 一种抗PD-L1/VEGF/TGF-β多特异性抗体及其用途
CN116829580A (zh) * 2020-12-15 2023-09-29 比卡拉治疗股份有限公司 用于融合蛋白的药物制剂
US20240082394A1 (en) * 2020-12-15 2024-03-14 Bicara Therapeutics Inc. Combination therapy for the treatment of cancer
WO2022174451A1 (zh) * 2021-02-22 2022-08-25 浙江道尔生物科技有限公司 一种具有抗癌活性的多结构域融合蛋白
WO2022187583A1 (en) * 2021-03-05 2022-09-09 Shattuck Labs, Inc. Combination therapies with tim-3-based chimeric proteins
AU2022229900A1 (en) * 2021-03-05 2023-10-05 Shattuck Labs, Inc. Combination therapies with sirp alpha-based chimeric proteins
JP2024511319A (ja) 2021-03-09 2024-03-13 ゼンコア インコーポレイテッド Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
CA3222357A1 (en) 2021-07-09 2023-01-12 Bertolt Kreft Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases
CN118159560A (zh) * 2021-08-27 2024-06-07 希拉诺提克斯有限公司 与B7-H3和TGFβ特异性结合的双特异性分子及其用途
US11492394B1 (en) 2021-10-29 2022-11-08 Nascent Biotech, Inc. Kits and containers for treating vimentin expressing tumors
IL314280A (en) 2022-01-28 2024-09-01 35Pharma Inc Type IIB activin receptor variants and their uses
WO2023150788A2 (en) * 2022-02-07 2023-08-10 Ubiquitx Beta-catenin protein degradation
EP4653010A1 (en) 2024-05-14 2025-11-26 35Pharma Inc. Activin receptor type iib traps for use in improving body composition

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ230786A (en) 1988-09-28 1991-11-26 Lilly Co Eli A method of reducing the heterogeneity of secreted monoclonal antibodies
RU2120475C1 (ru) 1990-05-17 1998-10-20 Макс-Планк-Гезельшафт Цур Фердерунг дер Виссеншафтен е.ф. Способ получения представляющего интерес полипептида, гибридная днк (варианты), слитый белок (варианты)
WO1998033914A1 (en) * 1997-01-31 1998-08-06 University Of Rochester Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
AU778611B2 (en) * 1999-08-09 2004-12-16 Merck Patent Gmbh Multiple cytokine-antibody complexes
WO2001055343A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
UA83791C2 (ru) 2001-04-13 2008-08-26 Байоджен Айдек Ма Инк. Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1
ES2535877T3 (es) * 2006-06-19 2015-05-18 Asklepios Biopharmaceutical, Inc. Genes de Factor VIII y Factor IX modificados y vectores para la terapia génica
CA2671875A1 (en) 2006-12-22 2008-06-03 Ares Trading S.A. Analytical method for analyzing c-terminus truncation
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
KR101661770B1 (ko) * 2007-09-21 2016-10-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 표적화된 인터페론이 강력한 아폽토시스 및 항-종양 활성을 발휘함
AU2009223784A1 (en) * 2008-03-08 2009-09-17 Immungene, Inc. Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
JP5304275B2 (ja) 2009-01-29 2013-10-02 Ｊｎｃ株式会社 アポクライティン−ｉｉをコードするコドン最適化核酸およびその使用方法
US8470552B2 (en) * 2009-10-12 2013-06-25 Keck Graduate Institute Strategy to reduce lactic acid production and control PH in animal cell culture
WO2011102845A1 (en) 2010-02-18 2011-08-25 Transtech Pharma, Inc. Rage fusion protein compositions and methods of use
IL300733B1 (en) 2010-03-05 2025-10-01 Univ Johns Hopkins Compositions and methods for antibodies and fusion proteins targeted for immune modulation
CA2810668A1 (en) * 2010-09-08 2012-03-15 Halozyme, Inc. Methods for assessing and identifying or evolving conditionally active therapeutic proteins
EP2702164B8 (en) 2011-04-29 2016-03-16 Biocon Research Limited A method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof
MY166973A (en) * 2011-04-29 2018-07-27 Biocon Res Limited Methods for reducing accumulation of lactate during culturing and method for producing polypeptide
US10323081B2 (en) 2011-07-06 2019-06-18 Genmag A/S Modulation of complement-dependent cytotoxicity through modifications of the C-terminus of antibody heavy chains
SE536913C2 (sv) 2012-03-08 2014-10-28 Gambro Lundia Ab Komposition för dialys
EP4219536A3 (en) * 2012-04-30 2023-08-23 Biocon Limited Targeted/immunomodulatory fusion proteins and methods for making same
PT2970512T (pt) * 2013-03-12 2019-01-17 Biocon Ltd Proteínas de fusão imunomoduladoras e métodos para produção das mesmas

Also Published As

Publication number Publication date
MY174248A (en) 2020-04-01
EP2844667B1 (en) 2018-05-30
PT2844667T (pt) 2018-08-06
WO2013164694A1 (en) 2013-11-07
US10144934B2 (en) 2018-12-04
EP3489254A1 (en) 2019-05-29
CA3004695C (en) 2020-08-04
JP6357467B2 (ja) 2018-07-11
US11028399B2 (en) 2021-06-08
NZ701821A (en) 2016-06-24
ES2938182T3 (es) 2023-04-05
RU2636342C2 (ru) 2017-11-22
NZ729633A (en) 2019-03-29
AU2013255542B2 (en) 2016-12-22
CA2947354A1 (en) 2013-11-07
US20160237155A1 (en) 2016-08-18
US20160168260A1 (en) 2016-06-16
RU2014145158A (ru) 2016-06-20
US9758582B2 (en) 2017-09-12
AU2013255542A1 (en) 2014-11-20
CN104334573A (zh) 2015-02-04
EP3489254B9 (en) 2022-12-21
US20180066057A1 (en) 2018-03-08
PL3489254T3 (pl) 2023-01-30
CA2947354C (en) 2024-03-19
DK3489254T3 (da) 2022-11-07
JP2018127447A (ja) 2018-08-16
EP3333183B1 (en) 2023-02-22
EP3489254B1 (en) 2022-09-28
HK1202295A1 (en) 2015-09-25
US20210301296A1 (en) 2021-09-30
AU2013255542C1 (en) 2017-06-22
JP7307218B2 (ja) 2023-07-11
US20130287802A1 (en) 2013-10-31
CN110041431A (zh) 2019-07-23
US9809651B2 (en) 2017-11-07
EP2844667A1 (en) 2015-03-11
US12049632B2 (en) 2024-07-30
NZ714549A (en) 2016-10-28
JP7035115B2 (ja) 2022-03-14
JP6714620B2 (ja) 2020-06-24
CA2871706C (en) 2019-12-03
HK1253051A1 (zh) 2019-06-06
EP3333183A1 (en) 2018-06-13
EP4219536A3 (en) 2023-08-23
PT3489254T (pt) 2022-12-30
PL2844667T3 (pl) 2018-10-31
BR112014027131A2 (pt) 2017-06-27
US9340617B2 (en) 2016-05-17
US20190169621A1 (en) 2019-06-06
US10385348B2 (en) 2019-08-20
US20140356362A1 (en) 2014-12-04
JP2022075730A (ja) 2022-05-18
CA3004695A1 (en) 2013-11-07
JP2020138977A (ja) 2020-09-03
DK2844667T3 (en) 2018-07-30
US20170233747A1 (en) 2017-08-17
CA3212759A1 (en) 2013-11-07
CN108503711A (zh) 2018-09-07
EP4219536A2 (en) 2023-08-02
AU2017201572B2 (en) 2018-09-27
AU2017201572A1 (en) 2017-03-30
US11060097B2 (en) 2021-07-13
CA2871706A1 (en) 2013-11-07
HK1251589A1 (en) 2019-02-01
US8815247B2 (en) 2014-08-26
US20250011794A1 (en) 2025-01-09
CN110563850A (zh) 2019-12-13
JP2015516815A (ja) 2015-06-18
NZ722585A (en) 2017-03-31
US20190367929A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
ES2678696T3 (es) Proteínas de fusión dirigidas/inmunomoduladoras y métodos de preparación de las mismas
CY1122691T1 (el) Πρωτεϊνες δεσμευσης αλβουμινης ορου
AR127516A2 (es) VARIANTES DE Fc Y MÉTODOS PARA SU PRODUCCIÓN
CY1120471T1 (el) Αντισωματα κατα του cd70
BRPI0923346A2 (pt) Proteinas em super-helice antiparalela de cadeia simples
AR092050A1 (es) Proteinas de fusion de anticuerpos e interleuquina 10 y usos de las mismas
MX360946B (es) Inmunoglobulinas portadoras y usos de las mismas.
BR112012015740A2 (pt) anticorpos de anti-flt3 e metodos de uso dos mesmos
HRP20220214T1 (hr) Imunomodulacijska sredstva
AR090047A1 (es) Dominio variable dual de inmunoglobulinas y sus usos
CL2013001124A1 (es) Anticuerpo aislado o una proteína que comprende una porción de enlace de antígeno de un anticuerpo dirigido contra un polipéptido de cd40; composicion farmacéutica que comprende dicho anticuerpo; ácido nucleico que codifica el anticuerpo; vector de clonación; proceso de producción del anticuerpo.
GT201200058A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
EP4406612A8 (en) Anti-cd70 antibody drug conjugates
AR092712A1 (es) Una proteina con actividad cetosa 3-epimerasa
RU2019124678A (ru) Слитый белок pd1-41bbl и способы его применения
TR201905619T4 (tr) Alerji aşısı olarak peptit taşıyıcı füzyon proteinleri.
BR112014008694A2 (pt) moléculas de ácido nucleico policistrônico recombinante
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
EA201391632A1 (ru) Аминокислотные последовательности, направленные против il-17a, il-17f и/или il-17a/f, и содержащие их полипептиды
BR112012011305A2 (pt) uso de uma proteína homóloga a uma proteína meab para aumentar a atividade enzimática de uma mutase do ácido 3-hidroxicarboxílico-coa
BRPI1014016B8 (pt) anticorpos humanizados para receptor tipo toll 2 e usos dos mesmos.
CY1119149T1 (el) Αντικαρκινικη πρωτεϊνη συντηξης
BR112014024282A2 (pt) anticorpos ligantes ao receptor b1 da bradicinina
MX356162B (es) Sistema de expresion y secrecion.
UA115436C2 (uk) Протираковий злитий протеїн